Are you planning to extend this regulatory flexibility? Recently, several researchers, companies, patient organizations and others came to the committee to warn against the implementation of the new Patented Medicine Prices Review Board guidelines. They said the guidelines would make Canada and the provinces much less attractive for clinical trials.
Have you ensured that the price we pay for our medicines is not excessive? What steps have you taken to control the price of drugs related to this COVID‑19 research here in Canada?